高剂量达比加群在模拟体外循环中作为有效抗凝剂的人血研究
研究探讨达比加群在模拟体外循环(CPB)120分钟中的抗凝效果。采用人血进行序贯实验,包括体外血栓弹力图(TEG)剂量反应、Chandler环路及模拟CPB装置。结果显示高剂量达比加群可维持血液流动性并防止肉眼血栓形成,且伊达鲁珠单抗可逆转其抗凝作用。
要点
- 高剂量达比加群可维持模拟CPB 120分钟无肉眼血栓。
- 达比加群剂量依赖性延长R时间并抑制凝血传播动力学。
- 伊达鲁珠单抗可逆转达比加群的抗凝效果。
核心结论
- 高剂量达比加群可有效抗凝并维持模拟CPB 120分钟血液流动性。
- 伊达鲁珠单抗可逆转达比加群的抗凝作用。
研究设计与样本
- 研究分两步序贯进行,均使用健康供者人血。
- 先体外加入递增浓度达比加群,用快速TEG测量抗凝效应。
- 再以高浓度达比加群置于Chandler环路评估120分钟血液流动性。
- 最后在模拟CPB装置中测试3种剂量达比加群。
主要发现
- 体外实验中达比加群剂量依赖性延长R时间并降低凝血传播动力学(Angle、MRTG、TMRTG)。
- Chandler环路中仅高于预期的高剂量达比加群可防止120分钟血栓形成。
- 伊达鲁珠单抗在体外和Chandler环路中均缩短R时间并逆转抗凝。
- 模拟CPB中达比加群防止120分钟肉眼血栓形成。
关键数值与推荐
- 主要结局为成功完成120分钟模拟CPB且无肉眼血栓。
- 达比加群在体外剂量依赖性延长R时间。
- Chandler环路中仅高剂量达比加群维持120分钟无血栓。
临床怎么用
- 达比加群可作为CPB肝素替代的潜在候选,但需高剂量。
- 伊达鲁珠单抗可用于逆转达比加群抗凝。
- 临床转化前需进一步验证剂量与安全性。
局限性
- 研究为模拟CPB的体外实验,非临床体内研究。
- 样本仅来自健康供者人血,未涉及患者。
- 达比加群所需剂量高于预期,临床适用性待评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently no ideal alternative exists for heparin for cardiopulmonary bypass (CPB). Dabigatran is a direct thrombin inhibitor for which a reversal agent exists. The primary end point of the study was to explore whether Dabigatran was an effective anticoagulant for 120 minutes of simulated CPB. METHODS: The study was designed in 2 sequential steps. Throughout, human blood from healthy donors was used for each experimental step. Initially, increasing concentrations of Dabigatran were added to aliquots of fresh whole blood, and the anticoagulant effect measured using kaolin/tissue factor-activated thromboelastography (rapidTEG). The dynamics of all thromboelastography (TEG) measurements were studied with repeated measures analysis of variance (ANOVA). Based on these data, aliquots of blood were treated with high-concentration Dabigatran and placed in a Chandler loop as a simple ex vivo bypass model to assess whether Dabigatran had sufficient anticoagulant effects to maintain blood fluidity for 2 hours of continuous contact with the artificial surface of the PVC tubing. Idarucizumab, humanized monoclonal antibody fragment, was used to verify the reversibility of Dabigatran effects. Finally, 3 doses of Dabigatran were tested in a simulated CPB setup using a heart-lung machine and a commercially available bypass circuit with an arteriovenous (A-V) loop. The primary outcome was the successful completion of 120 minutes of simulated CPB with dabigatran anticoagulation, defined as lack of visible thrombus. Thromboelastographic reaction (R) time was measured repeatedly in each bypass simulation, and the circuits were continuously observed for clot. Scanning Electron Microscopy (SEM) was used to visualize fibrin formation in the filters meshes during CPB. RESULTS: In in vitro blood samples, Dabigatran prolonged R time and reduced the dynamics of clot propagation (as measured by speed of clot formation [Angle], maximum rate of thrombus generation [MRTG], and time to maximum rate of thrombus generation [TMRTG]) in a dose-dependent manner. In the Chandler Loop, high doses of Dabigatran prevented clot formation for 120 minutes, but only at doses higher than expected. Idarucizumab decreased R time and reversed anticoagulation in both in vitro and Chandler Loops settings. In the A-V loop bypass simulation, Dabigatran prevented gross thrombus generation for 120 minutes of simulated CPB. CONCLUSIONS: Using sequential experimental approaches, we showed that direct thrombin inhibitor Dabigatran in high doses maintained anticoagulation of blood for simulated CPB. Idarucizumab reduced time for clot formation reversing the anticoagulation action of Dabigatran.
引用
- Nadtochiy SM, Baldzizhar A, Stefanos T, et al. High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood. Anesth Analg. 2021. PMID: 32833714. doi:10.1213/ANE.0000000000005089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。